生长素释放肽在肥胖治疗中的潜在应用价值研究进展  

Advances in the potential application value of ghrelin in treating obesity

作　　者：向林 江云颂 程吕佳 关炳生 杨景哥[1] Xiang Lin;Jiang Yunsong;Cheng Lvji;Guang Bingsheng;Yang Jingge(Department of Gastrointestinal Surgery,the First Affiliated Hospital of Jinan University,Guangzhou 510630,China)

机构地区：[1]暨南大学附属第一医院胃肠外科,广州510630

出　　处：《中华肥胖与代谢病电子杂志》2024年第4期235-241,共7页Chinese Journal Of Obesity and Metabolic Diseases:Electronic Edition

基　　金：广东省医学科学技术研究基金项目(A2024313);广州市科技计划项目(202201020064)

摘　　要：生长素释放肽(饥饿素)是一种主要从胃分泌到血液中的短肽类激素,可诱导迅速增加能量摄入,并可能长期诱导体重增加和导致肥胖。禁食可提高血清中的生长素释放肽水平,而进餐后则被抑制。因此,抑制生长素释放肽信号可能在肥胖治疗方面具有一定潜力。既往研究已经探索了许多不同方法抑制生长素释放肽系统以治疗肥胖,但目前仍未有基于拮抗生长素释放肽系统疗法应用于临床。本文探讨了生长素释放肽在控制食欲中的作用,分析总结抑制生长素释放肽系统的不同方法,并评估生长素释放肽作为抗肥胖疗法的潜力。Ghrelin,a short peptide hormone secreted primarily from the stomach into the blood,induces a rapid increase in energy intake and may induce weight gain and obesity in the long term.Ghrelin levels in serum were increased by fasting but suppressed after meals.Therefore,inhibiting ghrelin signaling may have some potential in treating weight loss.Previous studies have explored different approaches to inhibit the ghrelin system for treating obesity,but until now,no therapy based on antagonizing the ghrelin system has been applied in clinical practice.This article discusses the role of ghrelin in appetite control in humans,reviews different approaches to inhibit the ghrelin system,and evaluates their potential as antiobesity therapies.

关 键 词：肥胖 生长素释放肽/饥饿素 生长素释放肽受体1a 肝脏表达抗菌肽-2 药物开发 

分 类 号：R589.2[医药卫生—内分泌]